Delivery Order SPE2DR25D1053-SPE2DR26FV233
Award Date 1/5/26
Potential Completion Date 1/6/26
Potential Value $3.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,551.54 for Ruxience 500 mg/50 mL vials on November 25, 2025, with completion expected by November 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, representing the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,652.96 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials. This non-competitive, firm fixed-price delivery order was executed on October 28, 2025, with an ultimate completion date of October 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, reflecting the...
- The Defense Logistics Agency awarded a $6,461.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 500 mg/50 mL vials of Ruxience, a biosimilar medication used to treat various cancers and autoimmune conditions. This non-competitive delivery order was issued on December 23, 2025, with an ultimate completion date of December 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ruxience 500 mg/50 ml vials, a biosimilar monoclonal antibody used in cancer and autoimmune disease treatment. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $4,892.20 and an ultimate completion date of August 15, 2025. The contract involves no set-aside designation and utilizes AmerisourceBergen's place of performance in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,092.68 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of December 5, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion comprehensive pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $8,818.09 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer and immunological disorder treatment. This firm fixed price delivery order was issued on October 30, 2025, with an ultimate completion date of October 31, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $14,773.25 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials. This competitively awarded, firm fixed-price delivery order was issued on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in cancer treatment and other therapeutic applications, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $1,939.51 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 ml vials on December 15, 2025, with completion scheduled for December 16, 2025. This competitively awarded, firm fixed-price order represents a continuation of the company's substantial pharmaceutical supply relationship with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...